{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:11:13Z","timestamp":1791670273066,"version":"4.3.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s13555-026-01769-z","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T15:08:24Z","timestamp":1778512104000},"page":"2587-2601","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Symposium on Hidradenitis Suppurativa Advances 2025 Proceedings"],"prefix":"10.1007","volume":"16","author":[{"given":"Claire S.","family":"Chung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenan","family":"Kherallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazrin","family":"Ashina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela E.","family":"Beraja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuj","family":"Budhiraja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Dienes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mollye","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raed","family":"Alhusayen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammy","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadar","family":"Lev-Tov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathryn","family":"Sibbald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Piguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"1769_CR1","doi-asserted-by":"publisher","unstructured":"Abstracts of the 10th Annual Symposium on Hidradenitis Suppurativa Advances 2025. Dermatol Ther [Internet]. 2025 [cited 17 Dec 2025]; https:\/\/doi.org\/10.1007\/s13555-025-01579-9.","DOI":"10.1007\/s13555-025-01579-9"},{"key":"1769_CR2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/bjd\/ljad345","volume":"190","author":"JG Krueger","year":"2024","unstructured":"Krueger JG, Frew J, Jemec GBE, Kimball AB, Kirby B, Bechara FG, et\u00a0al. Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape. Br J Dermatol. 2024;190:149\u201362. https:\/\/doi.org\/10.1093\/bjd\/ljad345.","journal-title":"Br J Dermatol"},{"key":"1769_CR3","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.jaad.2020.05.007","volume":"83","author":"JW Frew","year":"2020","unstructured":"Frew JW, Navrazhina K, Grand D, Sullivan-Whalen M, Gilleaudeau P, Garcet S, et\u00a0al. The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: an open-label cohort study. J Am Acad Dermatol. 2020;83:1341\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2020.05.007.","journal-title":"J Am Acad Dermatol"},{"key":"1769_CR4","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.jaad.2021.07.035","volume":"86","author":"K Navrazhina","year":"2022","unstructured":"Navrazhina K, Garcet S, Frew JW, Zheng X, Coats I, Guttman-Yassky E, et\u00a0al. The inflammatory proteome of hidradenitis suppurativa skin is more expansive than that of psoriasis vulgaris. J Am Acad Dermatol. 2022;86:322\u201330. https:\/\/doi.org\/10.1016\/j.jaad.2021.07.035.","journal-title":"J Am Acad Dermatol"},{"key":"1769_CR5","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1016\/j.jaci.2020.12.651","volume":"147","author":"K Navrazhina","year":"2021","unstructured":"Navrazhina K, Frew JW, Gilleaudeau P, Sullivan-Whalen M, Garcet S, Krueger JG. Epithelialized tunnels are a source of inflammation in hidradenitis suppurativa. J Allergy Clin Immunol. 2021;147:2213\u201324. https:\/\/doi.org\/10.1016\/j.jaci.2020.12.651.","journal-title":"J Allergy Clin Immunol"},{"key":"1769_CR6","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.jaci.2023.05.012","volume":"152","author":"J Kim","year":"2023","unstructured":"Kim J, Lee J, Li X, Lee HS, Kim K, Chaparala V, et\u00a0al. Single-cell transcriptomics suggest distinct upstream drivers of IL-17A\/F in hidradenitis versus psoriasis. J Allergy Clin Immunol. 2023;152:656\u201366. https:\/\/doi.org\/10.1016\/j.jaci.2023.05.012.","journal-title":"J Allergy Clin Immunol"},{"key":"1769_CR7","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jaci.2021.05.027","volume":"149","author":"K Navrazhina","year":"2022","unstructured":"Navrazhina K, Garcet S, Zheng X, Hur HB, Frew JW, Krueger JG. High inflammation in hidradenitis suppurativa extends to perilesional skin and can be subdivided by lipocalin-2 expression. J Allergy Clin Immunol. 2022;149:135-144.e12. https:\/\/doi.org\/10.1016\/j.jaci.2021.05.027.","journal-title":"J Allergy Clin Immunol"},{"key":"1769_CR8","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.jid.2024.07.005","volume":"145","author":"N Shishido-Takahashi","year":"2025","unstructured":"Shishido-Takahashi N, Garcet S, Cueto I, Miura S, Li X, Rambhia D, et\u00a0al. Hepatocyte growth factor has unique functions in keratinocytes that differ from those of IL-17A and TNF and may contribute to inflammatory pathways in hidradenitis suppurativa. J Invest Dermatol. 2025;145:536-547.e7. https:\/\/doi.org\/10.1016\/j.jid.2024.07.005.","journal-title":"J Invest Dermatol"},{"key":"1769_CR9","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.17268.2","volume":"7","author":"JW Frew","year":"2019","unstructured":"Frew JW, Hawkes JE, Krueger JG. A systematic review and critical evaluation of immunohistochemical associations in hidradenitis suppurativa. F1000Res. 2019;7:1923. https:\/\/doi.org\/10.12688\/f1000research.17268.2.","journal-title":"F1000Res"},{"key":"1769_CR10","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/bjd.21275","volume":"187","author":"A Garg","year":"2022","unstructured":"Garg A, Krueger JG. Raising the bar for efficacy in hidradenitis suppurativa: a rationale for combination targeted therapies. Br J Dermatol. 2022;187:414\u20135. https:\/\/doi.org\/10.1111\/bjd.21275.","journal-title":"Br J Dermatol"},{"key":"1769_CR11","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1016\/j.jaad.2025.08.024","volume":"93","author":"HL Cole","year":"2025","unstructured":"Cole HL, Mumber HE, Dugas JN, Forman LS, Lam CS, Shen LY. Prevalence of comorbidities among pediatric patients with hidradenitis suppurativa at a safety-net hospital. J Am Acad Dermatol. 2025;93:1600\u20132. https:\/\/doi.org\/10.1016\/j.jaad.2025.08.024.","journal-title":"J Am Acad Dermatol"},{"key":"1769_CR12","doi-asserted-by":"publisher","unstructured":"Singh R, Mohney L, Senthilnathan A, Feldman- SR, Pichardo RO. Educational attainment is inversely correlated with hidradenitis suppurativa severity. Dermatol Online J [Internet]. 2022 [cited 14 Dec 2025];28. https:\/\/doi.org\/10.5070\/D328357842.","DOI":"10.5070\/D328357842"},{"key":"1769_CR13","doi-asserted-by":"publisher","unstructured":"Lau CB, Xia E, Shen LY. Quality of life in pediatric hidradenitis suppurativa: a cross-sectional study. Pediatr Dermatol [Internet]. [cited 14 Dec 2025];n\/a. https:\/\/doi.org\/10.1111\/pde.70042.","DOI":"10.1111\/pde.70042"},{"key":"1769_CR14","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1001\/jamadermatol.2021.4741","volume":"158","author":"S Ravi","year":"2022","unstructured":"Ravi S, Miles JA, Steele C, Christiansen MK, Sayed CJ. Patient impressions and outcomes after clinic-based hidradenitis suppurativa surgery. JAMA Dermatol. 2022;158:132\u201341. https:\/\/doi.org\/10.1001\/jamadermatol.2021.4741.","journal-title":"JAMA Dermatol"},{"key":"1769_CR15","doi-asserted-by":"publisher","unstructured":"Haller CN, Nguyen CM, England ME, Diaz LZ, Pe\u00f1a-Robichaux V. Adolescent Satisfaction After Deroofing Surgery for Hidradenitis Suppurativa. Pediatr Dermatol [Internet]. [cited 14 Dec 2025];n\/a. https:\/\/doi.org\/10.1111\/pde.70019.","DOI":"10.1111\/pde.70019"},{"key":"1769_CR16","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.jid.2021.05.036","volume":"142","author":"S McCarthy","year":"2022","unstructured":"McCarthy S, Barrett M, Kirthi S, Pellanda P, Vlckova K, Tobin A-M, et\u00a0al. Altered skin and gut microbiome in hidradenitis suppurativa. J Invest Dermatol. 2022;142:459-468.e15. https:\/\/doi.org\/10.1016\/j.jid.2021.05.036.","journal-title":"J Invest Dermatol"},{"key":"1769_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/exd.15087","volume":"33","author":"SC Williams","year":"2024","unstructured":"Williams SC, Garcet S, Hur H, Miura S, Gonzalez J, Navrazhina K, et\u00a0al. Gram negative anaerobes elicit a robust keratinocytes immune response with potential insights into HS pathogenesis. Exp Dermatol. 2024;33:e15087. https:\/\/doi.org\/10.1111\/exd.15087.","journal-title":"Exp Dermatol"},{"key":"1769_CR18","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s40257-025-00940-0","volume":"26","author":"CB Dagenet","year":"2025","unstructured":"Dagenet CB, Lee KH, Sayed C, Hsiao JL, Shi VY. Comprehensive and updated algorithm of hidradenitis suppurativa management from the experts. Am J Clin Dermatol. 2025;26:487\u201397. https:\/\/doi.org\/10.1007\/s40257-025-00940-0.","journal-title":"Am J Clin Dermatol"},{"key":"1769_CR19","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jaad.2020.09.039","volume":"85","author":"KT Savage","year":"2021","unstructured":"Savage KT, Singh V, Patel ZS, Yannuzzi CA, McKenzie-Brown AM, Lowes MA, et\u00a0al. Pain management in hidradenitis suppurativa and a proposed treatment algorithm. J Am Acad Dermatol. 2021;85:187\u201399. https:\/\/doi.org\/10.1016\/j.jaad.2020.09.039.","journal-title":"J Am Acad Dermatol"},{"key":"1769_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-025-04121-1","volume":"317","author":"A Soltoff","year":"2025","unstructured":"Soltoff A, Gold S, Echuri H, Curseen K, Soodalter J, Kavalieratos D, et\u00a0al. Empathy, expertise, and expeditious communication: identifying how people with hidradenitis suppurativa experience outpatient palliative care. Arch Dermatol Res. 2025;317:687. https:\/\/doi.org\/10.1007\/s00403-025-04121-1.","journal-title":"Arch Dermatol Res"},{"key":"1769_CR21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/bjd\/ljac018","volume":"188","author":"LAV Orenstein","year":"2023","unstructured":"Orenstein LAV, Salame N, Siira MR, Urbanski M, Flowers NI, Echuri H, et\u00a0al. Pain experiences among those living with hidradenitis suppurativa: a qualitative study. Br J Dermatol. 2023;188:41\u201351. https:\/\/doi.org\/10.1093\/bjd\/ljac018.","journal-title":"Br J Dermatol"},{"key":"1769_CR22","doi-asserted-by":"publisher","unstructured":"Deng Z, Wang S, Wu C, Wang C. IL-17 inhibitor-associated inflammatory bowel disease: a study based on literature and database analysis. Front Pharmacol. 2023;14:1124628. https:\/\/doi.org\/10.3389\/fphar.2023.1124628.","DOI":"10.3389\/fphar.2023.1124628"},{"key":"1769_CR23","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s13555-023-00913-3","volume":"13","author":"AB Kimball","year":"2023","unstructured":"Kimball AB, Prens EP, Passeron T, Maverakis E, Turchin I, Beeck S, et\u00a0al. Efficacy and safety of Risankizumab for the treatment of hidradenitis suppurativa: a phase 2, randomized, placebo-controlled trial. Dermatol Ther. 2023;13:1099\u2013111. https:\/\/doi.org\/10.1007\/s13555-023-00913-3.","journal-title":"Dermatol Ther"},{"key":"1769_CR24","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1001\/jamadermatol.2019.0759","volume":"155","author":"MO Machado","year":"2019","unstructured":"Machado MO, Stergiopoulos V, Maes M, Kurdyak PA, Lin P-Y, Wang L-J, et\u00a0al. Depression and anxiety in adults with hidradenitis suppurativa: a systematic review and meta-analysis. JAMA Dermatol. 2019;155:939\u201345. https:\/\/doi.org\/10.1001\/jamadermatol.2019.0759.","journal-title":"JAMA Dermatol"},{"key":"1769_CR25","doi-asserted-by":"publisher","first-page":"249","DOI":"10.31887\/DCNS.2015.17.3\/ggoodwin","volume":"17","author":"GM Goodwin","year":"2015","unstructured":"Goodwin GM. The overlap between anxiety, depression, and obsessive-compulsive disorder. Dialogues Clin Neurosci. 2015;17:249\u201360. https:\/\/doi.org\/10.31887\/DCNS.2015.17.3\/ggoodwin.","journal-title":"Dialogues Clin Neurosci"},{"key":"1769_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/cells14080607","volume":"14","author":"C Hole","year":"2025","unstructured":"Hole C, Dhamsania A, Brown C, Ryznar R. Immune dysregulation in depression and anxiety: a review of the immune response in disease and treatment. Cells. 2025;14:607. https:\/\/doi.org\/10.3390\/cells14080607.","journal-title":"Cells"},{"key":"1769_CR27","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1007\/s00406-024-01864-2","volume":"275","author":"CD Moulton","year":"2025","unstructured":"Moulton CD, Malys M, Hopkins CWP, Rokakis AS, Young AH, Powell N. Activation of the interleukin-23\/Th17 axis in major depression: a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2025;275:1653\u201373. https:\/\/doi.org\/10.1007\/s00406-024-01864-2.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1769_CR28","doi-asserted-by":"publisher","first-page":"294","DOI":"10.4306\/pi.2013.10.3.294","volume":"10","author":"J-W Kim","year":"2013","unstructured":"Kim J-W, Kim Y-K, Hwang J-A, Yoon H-K, Ko Y-H, Han C, et\u00a0al. Plasma levels of IL-23 and IL-17 before and after antidepressant treatment in patients with major depressive disorder. Psychiatry Investig. 2013;10:294\u20139. https:\/\/doi.org\/10.4306\/pi.2013.10.3.294.","journal-title":"Psychiatry Investig"},{"key":"1769_CR29","doi-asserted-by":"publisher","unstructured":"Mamun-or-Rashid, Roknuzzaman ASM, Sarker R, Nayem J, Bhuiyan MA, Islam MR, et\u00a0al. Altered serum interleukin-17A and interleukin-23A levels may be associated with the pathophysiology and development of generalized anxiety disorder. Sci Rep. Nature Publishing Group; 2024;14:15097. https:\/\/doi.org\/10.1038\/s41598-024-66131-9.","DOI":"10.1038\/s41598-024-66131-9"},{"key":"1769_CR30","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.bbi.2019.06.001","volume":"81","author":"R Hou","year":"2019","unstructured":"Hou R, Ye G, Liu Y, Chen X, Pan M, Zhu F, et\u00a0al. Effects of SSRIs on peripheral inflammatory cytokines in patients with generalized anxiety disorder. Brain Behav Immun. 2019;81:105\u201310. https:\/\/doi.org\/10.1016\/j.bbi.2019.06.001.","journal-title":"Brain Behav Immun"},{"key":"1769_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/exd.15194","volume":"33","author":"SMT Sy","year":"2024","unstructured":"Sy SMT, Eder L, Jerome D, Obetta C, McKee H, Mirza R, et\u00a0al. Prevalence and predictors of inflammatory arthritis in hidradenitis suppurativa. Exp Dermatol. 2024;33:e15194. https:\/\/doi.org\/10.1111\/exd.15194.","journal-title":"Exp Dermatol"},{"key":"1769_CR32","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1159\/000514582","volume":"237","author":"N Almuhanna","year":"2021","unstructured":"Almuhanna N, Finstad A, Alhusayen R. Association between hidradenitis suppurativa and inflammatory arthritis: a systematic review and meta-analysis. Dermatology. 2021;237:740\u20137. https:\/\/doi.org\/10.1159\/000514582.","journal-title":"Dermatology"},{"key":"1769_CR33","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1093\/bjd\/ljae251","volume":"191","author":"W Lu","year":"2024","unstructured":"Lu W, Liu WW, Foolad N, Kwock JT, Jaleel T. Clinical characteristics associated with joint pain in hidradenitis suppurativa. Br J Dermatol. 2024;191:839\u201341. https:\/\/doi.org\/10.1093\/bjd\/ljae251.","journal-title":"Br J Dermatol"},{"key":"1769_CR34","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/pde.15759","volume":"42","author":"MT Ok","year":"2025","unstructured":"Ok MT, Googe PB, Sayed CJ, Burkhart C, Gulati AS, Nieman EL. The successful use of upadacitinib as monotherapy for hidradenitis suppurativa and ulcerative colitis in the setting of refractory disease. Pediatr Dermatol. 2025;42:353\u20137. https:\/\/doi.org\/10.1111\/pde.15759.","journal-title":"Pediatr Dermatol"},{"key":"1769_CR35","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/ijd.17498","volume":"64","author":"M Yamanaka-Takaichi","year":"2025","unstructured":"Yamanaka-Takaichi M, Nadalian S, Loftus EV, Ehman EC Jr, Todd A, Grimaldo AB, et\u00a0al. Differentiating clinical characteristics of perianal inflammatory bowel disease from perianal hidradenitis suppurativa. Int J Dermatol. 2025;64:520\u201330. https:\/\/doi.org\/10.1111\/ijd.17498.","journal-title":"Int J Dermatol"},{"key":"1769_CR36","unstructured":"Hidradenitis suppurativa providers [Internet]. [cited 2 Feb 2026]. https:\/\/www.hs-foundation.org\/hs-specialty-clinics. Accessed 2 Feb 2026."}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01769-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01769-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01769-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:53:25Z","timestamp":1780584805000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01769-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1769"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01769-z","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"26 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Raed Alhusayen is on the advisory board or has received honorarium from AbbVie, Bausch Health, Bio Jamp, Boehringer Ingelheim, Fresenius Kabi, Galderma, Incyte, Janssen, Novartis, Pfizer, Sandoz, Sanofi, and UCB, and has received investigator fees from AbbVie, Bausch Health, Incyte, Janssen, and Novartis. Dr. Stephanie Goldberg is on the advisory board for UCB and board of directors for the HS Foundation and HS Connect, and is president of the HS Coalition. Dr. Jennifer Hsiao is an editor-in-chief of\n                      Dermatology and Therapy\n                      , serves on the board of directors for the HS Foundation, and has served as an advisor, investigator, and\/or speaker for AbbVie, Amgen, Aclaris, AstraZeneca, Boehringer Ingelheim, Galderma, Incyte, Insmed, Moonlake, Navigator Medicines, Novartis, Oruka Therapeutics, Pfizer, Sanofi, Regeneron, and UCB; Dr. Jennifer Hsiao was not involved in the selection of peer reviewers of the manuscript or any of the subsequent editorial decisions. Dr. Hadar Lev-Tov has served as advisor, investigator, and\/or speaker for Incyte, Insmed, Moonlake, Novartis, and UCB. Dr. Cathryn Sibbald has received honorarium from Abbvie, Incyte, Leo Pharma, Novartis, Pfizer, Sanofi, UCB Pharma, and Sun Pharma; has participated in advisory boards with Arcutis, Sanofi, Pfizer, Sun Pharma, Incyte, and Eli Lily; and has participated in clinical trials with Bristol Myers Squibb, Incyte, Pfizer, and Sun Pharma. Dr. Vincent Piguet has received grants from AbbVie, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Incyte, Janssen, LEO Pharma, L\u2019Or\u00e9al, Novartis, Organon, Pfizer, Sandoz, and Sanofi; received payment or honoraria for speaking engagement from Sanofi; participated on an advisory board for LEO Pharma, Novartis, Sanofi, Union Therapeutics, Abbvie, and UCB; and received equipment donation from L\u2019Or\u00e9al. Dr. Martina Porter has served as consultant and investigator for AbbVie, Avalo Therapeutics, Arcutis, Aristea Therapeutics, Eli Lilly and Company, Incyte, Janssen, Merck, MoonLake Immunotherapeutics, Navigator Biosciences, Novartis, Pfizer, Prometheus, Sanofi, Sonoma Biotherapeutics, UCB, Ventyx, and Zura Bio; consultant for Almiral, FIDE, Otsuka, Propeller Biosciences, and Trifecta Clinical\/WCG; investigator for AnaptysBio, Bayer, Bristol Myers Squibb, OASIS Pharmaceuticals, and Regeneron; received royalties from Beth Israel Deaconess Medical Center; and received fellowship funding to institution from AbbVie. Claire S. Chung, Kenan Kherallah, Nazrin Ashina, Gabriela E. Beraja, Anuj Budhiraja, Serena Dienes, Mollye Goldberg, Grace Xiong, and Tammy Gonzalez have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}